Joel Waksman
Overview
Explore the profile of Joel Waksman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
70
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duvic M, Bates S, Piekarz R, Eisch R, Kim Y, Lerner A, et al.
Leuk Lymphoma
. 2017 Aug;
59(4):880-887.
PMID: 28853310
Cutaneous T-cell lymphomas (CTCL) are a group of non-Hodgkin lymphomas that typically present in the skin but can progress to systemic involvement. The optimal treatment for patients who relapse from...
2.
Bethoux F, Fatemi A, Fowler E, Marciniak C, Mayadev A, Waksman J, et al.
Clin Ther
. 2017 Jan;
39(2):337-346.
PMID: 28131322
Purpose: The goal of this study was to evaluate the safety and tolerability of dalfampridine extended release (D-ER) in a pilot study of adults with cerebral palsy (CP) and limited...
3.
Foss F, Duvic M, Lerner A, Waksman J, Whittaker S
Clin Lymphoma Myeloma Leuk
. 2016 Sep;
16(11):637-643.
PMID: 27637428
Background: Tumor stage and folliculotropic mycosis fungoides are uncommon subtypes of cutaneous T-cell lymphoma (CTCL) with an aggressive disease course. Romidepsin is a histone deacetylase inhibitor approved by the US...
4.
Kim E, Kim Y, Rook A, Lerner A, Duvic M, Reddy S, et al.
Leuk Lymphoma
. 2015 Mar;
56(10):2847-54.
PMID: 25791237
Cutaneous T-cell lymphoma (CTCL) is a rare heterogeneous group of non-Hodgkin lymphomas that arises in the skin but can progress to systemic disease (lymph nodes, blood, viscera). Historically, in clinical...
5.
Lazaryan A, Hussein M, Reu F, Faiman B, Habecker B, Karam M, et al.
Am J Hematol
. 2013 Nov;
89(4):349-54.
PMID: 24273135
A previous interim report of MM-011, the first study that combined lenalidomide with anthracycline-based chemotherapy followed by lenalidomide maintenance for relapsed and/or refractory multiple myeloma (RRMM), showed promising safety and...
6.
Kim Y, Demierre M, Kim E, Lerner A, Rook A, Duvic M, et al.
Leuk Lymphoma
. 2012 Jul;
54(2):284-9.
PMID: 22839723
Patients with cutaneous T-cell lymphoma (CTCL) frequently experience severe pruritus that can significantly impact their quality of life. Romidepsin is approved by the US Food and Drug Administration (FDA) for...
7.
8.
Kollar C, Schneider H, Waksman J, Krusinska E
Clin Ther
. 2007 Aug;
29(6):1057-70.
PMID: 17692721
Background: Although nonprescription oral phenylephrine 10 mg has been judged "generally recognized as safe and effective" by the US Food and Drug Administration (FDA), its efficacy as a nasal decongestant...
9.
Xie T, Waksman J
Stat Med
. 2003 Sep;
22(18):2835-46.
PMID: 12953283
Many clinical trials involve the collection of data on the time to occurrence of the same type of multiple events within sample units, in which ordering of events is arbitrary...